NAPM seeks to keep antibiotics out of Waxman/Hatch exclusivity procedures if Sec. 507 is repealed.
NAPM HOPES TO KEEP ANTIBIOTICS OUTSIDE WAXMAN/HATCH EXCLUSIVITY provisions, David Weeda of the Washington, D.C. law firm Olsson, Frank & Weeda told the National Association of Pharmaceutical Manufacturers annual meeting Jan. 31 in Naples, Fla. Legislation to repeal the separate regulation of antibiotics under FD&C Act Sec. 507 is expected to be reintroduced this year, Weeda noted. NAPM wants to ensure that such a repeal does not overturn the exemption of antibiotics from the Waxman/Hatch amendments.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth